Enzo Biochem Ready to Reveal EGS21 Data (NYSE:ENZ)
Jay Garcilazo (November 17th, 2009) Writes:
Enzo Biochem Inc (NYSE:ENZ) has announced that their Vice President of Corporate Development, David Goldberg will speak about Company’s extensive oral immune regulation platform at the Windhover TA Partnerships 2009 Conference which will be held in Boston on Wednesday, November 18, 2009. The Company announced that Enzo Biochem’s EGS21, an orally administered beta glucosylceramide formulation, which is currently undergoing clinical study, has been named one of this year’s top 10 inflammatory and autoimmune projects to watch. The TA Partnership Conference is sponsored by Windhover Information Inc which is world’s leading publisher of science, technical and health information.
Enzo Biochem have already presented their EGS21 clinical studies data recently at the Liver Conference where they showed that the oral administration of EGS21 is safe and appears to be biologically active in patients
...

![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_2.gif)




